IMUGENE LIMITED — Capital/Financing Update 2004

Dec 2, 2004

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002.

Name of entity

IMUGENE LIMITED

ABN

99 009 179 551

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

• $\mathbf{1}$ ⁺Class of ⁺securities issued or to be issued
• $\mathcal{D}$ Number of ⁺securities issued or to be issued (if known) or maximum number which may be issued
• Principal terms of the ⁺securities $\mathcal{R}$ (eg, if options, exercise price and date; if partly expiry paid *securities, the amount outstanding and due dates for payment; if *convertible securíties, the conversion price and dates for conversion)

A. Ordinary shares \$0.50 Options $\mathbf{B}$ .

13,475,000 $A_{-}$ 2,695,000 $\mathbf{B}$ .

Fully paid ordinary shares A. $\mathbf{B}$ .

Options exercisable at \$0.50 on or before 31 January 2007

⁺ See chapter 19 for defined terms.

4	Do the securities rank equally in all respects from the date of allotment with an existing "class of quoted securities?	А. В.	Yes the Options quoted on ASX.	$N/A$ – the Company will seek to have
	If the additional securities do not rank equally, please state: the date from which they do the extent which to they ۰ participate for the next dividend, οf the case ā (in trust. distribution) or interest payment the extent to which they do not ۰ rank equally, other than $\overline{\mathbf{m}}$ relation to the next dividend, distribution or interest payment
5	Issue price or consideration	А. В.	\$0.25 each basis)	nil (free attaching option on a 1 for 5
6.	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)		dated 23 November 2004.	Placement to clients of Southern Cross Equities Limited to raise \$3,368,750 (before costs). Funds raised are to be used to augment working capital requirements of the Company and applied to the final commercialisation stage to progress the Company's animal health products through the regulatory approvals process as more particularly described in the ASX release
7	Dates of entering + securities into uncertificated holdings or despatch of certificates		2 December 2004
		Number		* Class
8	Number class and οf all securities quoted on ASX. (including the securities in clause 2 if applicable)	121,793,080		Ordinary shares

⁺ See chapter 19 for defined terms.

$\overline{Q}$ Number and ⁺class of a *securities not quoted on AS. (including the securities in claus 2 if applicable)

	Number	*Class
J1	2,261,485	Options exercisable at \$0.1125
X	10,633,333	Performance Options
5e	2,695,000	Options exercisable at \$0.50

$10$ Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Not Applicable

Part 2 - Bonus issue or pro rata issue

• $11$ Is security holder approval Not Applicable required?
• 12 Is the issue renounceable or non-Not Applicable renounceable?
  • Not Applicable
• Ratio in which the "securities will 13 be offered
• $14$ *Class of *securities to which the offer relates
• 15 *Record date determine fo entitlements

Not Applicable

Not Applicable

Not Applicable

• 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
• 17 Policy for deciding entitlements in Not Applicable relation to fractions

Names of countries in which the 18 entity has *security holders who will not be sent new issue documents

Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.

19 οf Closing date for receipt acceptances or renunciations

Not Applicable

Not Applicable

⁺ See chapter 19 for defined terms.

20	Names of any underwriters	Not Applicable
21	Amount of any underwriting fee or commission	Not Applicable
22	Names of any brokers to the issue	Not Applicable
23.	Fee or commission payable to the broker to the issue	Not Applicable
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	Not Applicable
25.	If the issue is contingent on *security holders' approval, the date of the meeting	Not Applicable
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	Not Applicable
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not Applicable
28	Date rights trading will begin (if Not Applicable applicable)
29	Date rights trading will end (if Not Applicable applicable)
30	How do *security holders sell their entitlements in full through a broker?	Not Applicable
31	How do "security holders sell part of their entitlements through a broker and accept for the balance?	Not Applicable

⁺ See chapter 19 for defined terms.

32 How do *security holders dispose of their entitlements (except by sale through a broker)?

33 ⁺Despatch date Not Applicable

Not Applicable

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

• 34 Type of securities (tick one)
• Securities described in Part 1 $(a)$
• $(b)$

All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

(If the additional securities do not form a new class, go to $43$ )

Tick to indicate you are providing the information or documents

35

If the "securities are "equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders

-36	If the securities are equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories $1 - 1.000$ $1,001 - 5,000$ $5,001 - 10,000$ $10,001 - 100,000$ $100.001$ and over
-37	A copy of any trust deed for the additional *securities

(now go to $43$ )

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of securities for which *quotation is sought	Not Applicable
39.	of "securities which $\vert$ Class: for quotation is sought	Not Applicable
40	Do the "securities rank equally in all respects from the date of allotment with an existing "class of quoted *securities?	Not Applicable
	If the additional securities do not rank equally, please state: the date from which they do the extent which to they participate for the next dividend, (in the case οf trust. a distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion οf	Not Applicable
	another security, clearly identify that other security)
42	Number and + class of all + securities quoted on ASX (including the securities in clause 38)	+ Class Number Not Applicable

(now go to $43$ )

⁺ See chapter 19 for defined terms.

All entities

Fees

43

Payment method (tick one)
$\left \begin{array}{c} \end{array} \right $ Cheque attached
Electronic payment made	Note: Payment may be made electronically if Appendix 3B is given to ASX electronically at the same time.
	Periodic payment as agreed with the home branch has been arranged Note: Arrangements can be made for employee incentive schemes that involve frequent issues of securities.

Quotation agreement

• *Quotation of our additional *securities is in ASX's absolute discretion. ASX may Ť quote the "securities on any conditions it decides.
• $\overline{2}$ We warrant the following to ASX.
• The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
• There is no reason why those *securities should not be granted *quotation.
• An offer of the "securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

• Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
• We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the *securities to be quoted, it has been provided at the time that we request that the "securities be quoted.
• If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.

$\div$ See chapter 19 for defined terms.

• $\overline{3}$ We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
• $\overline{4}$ We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the *securities begins. We acknowledge that $\overline{ASX}$ is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: ...................................... (Director/Company secretary)

Print name: MARK PEARCE

$\begin{tabular}{ll} \multicolumn{2}{l}{{\color{blue}{\bf{1}}}} & \multicolumn{2}{l}{\bf{2}} & \multicolumn{2}{l}{\bf{3}} & \multicolumn{2}{l}{\bf{4}} & \multicolumn{2}{l}{\bf{5}} & \multicolumn{2}{l}{\bf{6}} & \multicolumn{2}{l}{\bf{7}} & \multicolumn{2}{l}{\bf{8}} & \multicolumn{2}{l}{\bf{9}} & \multicolumn{2}{l}{\bf{1}} & \multicolumn{2}{l}{\bf{1}} & \multicolumn{2}{l}{\bf{1}} & \multicolumn{2}{l}{\bf{1}} & \multicolumn{2}{l}{\$

$+$ See chapter 19 for defined terms.

IMLIGE NA Manazarta (1999) - Manazarta (h. 1992)

LIMITED

Notice under Section 708A

3 December 2004

Imugene Limited (Company) issued 13.475,000 shares pursuant to an issue made to persons who came within one of the exemptions set out in Section 708 of the Corporations Act.

The issued shares are part of a class of securities quoted on Australian Stock Exchange Limited.

The Company gives this notice pursuant to Section 708A(5)(e) of the Corporations Act.

The shares were issued without disclosure to investors under Part 6D.2, in reliance on Section 708A(5) of the Corporations Act.

The Company, as at the date of this notice, has complied with:

• the provisions of Chapter 2M of the Corporations Act as they apply to $(a)$ the Company; and
• $(b)$ Section 674 of the Corporations Act.

There is no excluded information for the purposes of Sections 708A(7) and (8) of the Corporations Act.